Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
AssigneesThe Johns Hopkins Universtiy, The United States of America as represented by the Department of Health and Human Services
InventorsDrew M. Pardoll, Elizabeth Jaffee, Adam Adler, Suzanne L. Topalian, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.
Claims17
A method of inducing a systemic immune response to shared melanoma antigens in a mammal having melanoma, comprising:
- (a) providing cells of at least one melanoma cell line that
- (i) express a plurality of shared melanoma antigens that are shared with the melanoma of said mammal;
- (ii) are transfected with a nucleic acid vector encoding a cytokine that recruits antigen presenting cells and enhances antigen presentation;
- (iii) are allogeneic to said mammal;
- and
- (iv) are irradiated prior to step (b);
- (b) administering an effective number of said cells to said mammal, which cells express said plurality of shared melanoma antigens and functionally express said cytokine,
- thereby inducing a systemic immune response specific to said plurality of shared melanoma antigens.
A method of inducing an antitumor response in a mammal having melanoma, comprising:
- (a) providing cells of at least one melanoma cell line that
- (i) express a plurality of shared melanoma antigens that are shared with the melanoma of said mammal;
- (ii) are transfected with a nucleic acid vector encoding a cytokine that recruits antigen presenting cells and enhances antigen presentation;
- (iii) are allogeneic to said mammal;
- and
- (iv) are irradiated prior to step (b);
- (b) administering an effective number of said cells to said mammal, which cells express said plurality of shared melanoma antigens and functionally express said cytokine
- thereby inducing an antitumor response that is characterized by:
- (A) at least a 50% decrease in the sum of the products of maximal perpendicular diameters of all measurable lesions;
- (B) no evidence of new lesions, and
- (C) no progression of any preexisting lesions.
A method of inducing regression or attenuation of growth of melanoma in a mammal having melanoma, comprising:
- (a) providing cells of at least one melanoma cell line that
- (i) express a plurality of shared melanoma antigens that are shared with the melanoma of said mammal;
- (ii) are transfected with a nucleic acid vector encoding a cytokine that recruits antigen presenting cells and enhances antigen presentation;
- (iii) are allogeneic to said mammal;
- and
- (iv) are irradiated prior to step (b);
- (b) administering an effective number of said cells to said mammal, which cells express said plurality of shared melanoma antigens and functionally express said cytokine,
- thereby inducing a systemic immune response specific to said plurality of shared melanoma antigens of said melanoma, and thereby inducing said regression or attenuation of growth of said melanoma.
A method of inhibiting recurrent growth of a melanoma tumor in a mammal:
- (a) providing cells of at least one melanoma cell line that
- (i) express a plurality of shared melanoma antigens that are shared with the melanoma of said mammal;
- (ii) are transfected with a nucleic acid vector encoding a cytokine that recruits antigen presenting cells and enhances antigen presentation;
- (iii) are allogeneic to said mammal;
- and
- (iv) are irradiated prior to step (b);
- (b) administering an effective number of said cells to said mammal, which cells express said plurality of shared melanoma antigens and functionally express said cytokine,
- thereby inducing a systemic immune response specific to said plurality of shared melanoma antigens in said mammal, which immune response inhibits said recurrent growth of said melanoma tumor.
Dependencies are inferred from the claim text.